Paul Matteis
Stock Analyst at Stifel
(2.22)
# 2,734
Out of 5,157 analysts
127
Total ratings
42.17%
Success rate
-2.36%
Average return
Main Sectors:
Stocks Rated by Paul Matteis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Hold | $73 → $77 | $75.66 | +1.77% | 7 | Feb 26, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Hold | $25 → $24 | $22.54 | +6.48% | 7 | Feb 26, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $445 → $466 | $499.17 | -6.65% | 21 | Feb 13, 2026 | |
| QURE uniQure | Maintains: Buy | $50 → $40 | $18.26 | +119.06% | 3 | Dec 11, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $183 → $188 | $129.86 | +44.77% | 11 | Dec 11, 2025 | |
| LBRX LB Pharmaceuticals | Maintains: Buy | $27 → $35 | $24.02 | +45.71% | 2 | Dec 11, 2025 | |
| DYN Dyne Therapeutics | Maintains: Buy | $36 → $39 | $19.78 | +97.17% | 5 | Dec 11, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $495 → $508 | $322.38 | +57.58% | 16 | Dec 11, 2025 | |
| MPLT MapLight Therapeutics | Initiates: Buy | $28 | $18.97 | +47.60% | 1 | Nov 21, 2025 | |
| NMRA Neumora Therapeutics | Maintains: Hold | $2 → $3 | $3.26 | -7.98% | 3 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $73 → $61 | $60.89 | +0.18% | 11 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $144 → $202 | $188.41 | +7.21% | 7 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $12 | $6.16 | +94.81% | 3 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $94 | $93.01 | +1.06% | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $38.10 | -16.01% | 1 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $32 | $15.76 | +103.05% | 2 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $7.44 | +47.85% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $4 | $2.38 | +68.07% | 4 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $20.88 | -52.11% | 3 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $44 → $60 | $23.07 | +160.08% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $25 → $36 | $27.74 | +29.78% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $29.63 | +18.12% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $13.41 | +116.26% | 1 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $7.20 | +177.78% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $0.61 | +1,863.99% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $32 | $18.44 | +73.54% | 1 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $3.36 | +703.57% | 1 | Jul 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $64 | $13.75 | +365.45% | 1 | Feb 21, 2018 |
Ionis Pharmaceuticals
Feb 26, 2026
Maintains: Hold
Price Target: $73 → $77
Current: $75.66
Upside: +1.77%
ACADIA Pharmaceuticals
Feb 26, 2026
Maintains: Hold
Price Target: $25 → $24
Current: $22.54
Upside: +6.48%
Vertex Pharmaceuticals
Feb 13, 2026
Maintains: Hold
Price Target: $445 → $466
Current: $499.17
Upside: -6.65%
uniQure
Dec 11, 2025
Maintains: Buy
Price Target: $50 → $40
Current: $18.26
Upside: +119.06%
Neurocrine Biosciences
Dec 11, 2025
Maintains: Buy
Price Target: $183 → $188
Current: $129.86
Upside: +44.77%
LB Pharmaceuticals
Dec 11, 2025
Maintains: Buy
Price Target: $27 → $35
Current: $24.02
Upside: +45.71%
Dyne Therapeutics
Dec 11, 2025
Maintains: Buy
Price Target: $36 → $39
Current: $19.78
Upside: +97.17%
Alnylam Pharmaceuticals
Dec 11, 2025
Maintains: Buy
Price Target: $495 → $508
Current: $322.38
Upside: +57.58%
MapLight Therapeutics
Nov 21, 2025
Initiates: Buy
Price Target: $28
Current: $18.97
Upside: +47.60%
Neumora Therapeutics
Nov 17, 2025
Maintains: Hold
Price Target: $2 → $3
Current: $3.26
Upside: -7.98%
Nov 6, 2025
Downgrades: Hold
Price Target: $73 → $61
Current: $60.89
Upside: +0.18%
Nov 6, 2025
Upgrades: Buy
Price Target: $144 → $202
Current: $188.41
Upside: +7.21%
Sep 25, 2025
Maintains: Buy
Price Target: $9 → $12
Current: $6.16
Upside: +94.81%
May 29, 2025
Maintains: Buy
Price Target: $78 → $94
Current: $93.01
Upside: +1.06%
Mar 4, 2025
Initiates: Buy
Price Target: $32
Current: $38.10
Upside: -16.01%
Feb 27, 2025
Maintains: Buy
Price Target: $18 → $32
Current: $15.76
Upside: +103.05%
Feb 27, 2025
Initiates: Buy
Price Target: $11
Current: $7.44
Upside: +47.85%
Dec 16, 2024
Downgrades: Hold
Price Target: $4
Current: $2.38
Upside: +68.07%
Nov 13, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $20.88
Upside: -52.11%
Nov 12, 2024
Maintains: Buy
Price Target: $44 → $60
Current: $23.07
Upside: +160.08%
Nov 5, 2024
Upgrades: Buy
Price Target: $25 → $36
Current: $27.74
Upside: +29.78%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $29.63
Upside: +18.12%
Apr 30, 2024
Initiates: Buy
Price Target: $29
Current: $13.41
Upside: +116.26%
Nov 28, 2023
Initiates: Buy
Price Target: $20
Current: $7.20
Upside: +177.78%
Nov 14, 2023
Initiates: Buy
Price Target: $12
Current: $0.61
Upside: +1,863.99%
Jun 8, 2022
Maintains: Buy
Price Target: $54 → $32
Current: $18.44
Upside: +73.54%
Jul 26, 2021
Initiates: Buy
Price Target: $27
Current: $3.36
Upside: +703.57%
Feb 21, 2018
Maintains: Outperform
Price Target: $53 → $64
Current: $13.75
Upside: +365.45%